Brain methylmercury uptake in fetal, neonate, weanling, and adult rats.
Level 5 - mechanism / opinion, no new human data
Preclinical animal study without human data.
PubMed 30005196 · doi:10.1016/j.envres.2018.06.038
What was done
Researchers measured the time course of tissue mercury concentrations across developmental stages in rats following a subcutaneous injection of 0.08 µg (0.4 nmol) Hg/g methylmercury. In the prenatal experiment, pregnant dams received injections on embryonic days 17, 18, 18.5, 19, 19.5, or 20, with maternal and fetal tissues sampled on embryonic day 21. In the postnatal experiment, male rats were injected on postnatal days 1 (neonates), 35 (weanlings), or 56 (adults), with tissue mercury concentrations measured daily from 1 to 6 days post-injection.
What was found
Fetal brain mercury levels peaked 2 days after injection and were approximately 1.5 times higher than maternal brain levels. In neonates, brain mercury peaked faster and reached levels approximately 1.5 times higher than those in weanling or adult rats. Overall, peak brain mercury concentrations and the 24-hour brain-to-blood mercury ratio were highest in fetuses, followed by neonates, and systematically declined across later life stages. Absolute numerical concentrations and variance metrics were not reported in the abstract.
Why it matters
This study provides pharmacokinetic evidence that enhanced blood-to-brain transfer of methylmercury during early development contributes directly to fetal and neonatal vulnerability to mercury neurotoxicity.
Limits
The study was conducted entirely in rats, limiting direct translation to human pharmacokinetics. The total sample size (number of dams and pups evaluated) was not reported in the abstract, and long-term functional or neurotoxicological outcomes beyond tissue concentrations were not evaluated.
Cited by
- supports Developing fetuses are significantly more sensitive to mercury toxicity than adults.